Copy to clipboard 
Following the acquisition of Artoss, Biocomposites has added proprietary NanoBone technology to its product portfolio, a combination of nanocrystalline hydroxyapatite and silica gel – to provide optimal bone formation with easy handling.
Biocomposites acquired Artoss, a specialist manufacturer of bone graft substitutes for use in orthopedics, spine, foot/ankle and dentistry applications.
Artoss provides a range of bone graft substitute products that use its proprietary NanoBone technology – a combination of nanocrystalline hydroxyapatite and silica gel – to provide optimal bone formation with easy handling. The special structure of NanoBone is designed to activate the bone-forming forces of the body and lead to very rapid bone healing. In addition to Artoss’ lead product NanoBone SBX Putty, the company offers a wide range of indication-specific product variants that are all ready-to-use, directly from their applicators.
Located in Rostock, Germany, Artoss will continue to develop and manufacture products and will now be able to serve a greater number of surgeons and patients through access to Biocomposites’ established global distribution network.
Michael Harris, Chief Executive Officer of Biocomposites, said, “We are delighted to have completed this acquisition of Artoss. Adding the NanoBone range of products to our portfolio provides us with a new differentiated offering to help surgeons treat their patients and a platform from which to develop new ready-to-use products. Following on from our acquisitions of Subiton and Synimed last year, we have established ourselves as the go-to provider for surgeons requiring bone regeneration and/or managing infection in bone and soft tissue.”
Source: Biocomposites
